Sunshine Biopharma Gross Profit Growth & History (SBFM)
Sunshine Biopharma's gross profit was $12.3M for fiscal 2025.
View full Sunshine Biopharma company overviewSunshine Biopharma annual gross profit history
| Fiscal year | Period ended | Gross profit | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $12.3M | $1.6M | +14.86% |
| 2024 | 2024-12-31 | $10.7M | $2.3M | +27.95% |
| 2023 | 2023-12-31 | $8.3M | $6.6M | +391.53% |
| 2022 | 2022-12-31 | $1.7M | $1.6M | +1434.03% |
| 2021 | 2021-12-31 | $110,596 | $65,033 | +142.73% |
| 2020 | 2020-12-31 | $45,563 | $35,492 | +352.42% |
| 2019 | 2019-12-31 | $10,071 | $10,071 | — |
| 2018 | 2018-12-31 | $0 | $0 | — |
| 2017 | 2017-12-31 | $0 | — | — |
Sunshine Biopharma quarterly gross profit
| Fiscal quarter | Period ended | Gross profit | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $2.4M | −$996,184 | −29.10% |
| Q1 2026 | 2026-03-31 | $2.2M | −$549,436 | −20.12% |
| Q4 2025 | 2025-12-31 | $3.0M | −$64,204 | −2.08% |
| Q3 2025 | 2025-09-30 | $3.1M | $207,389 | +7.24% |
| Q2 2025 | 2025-06-30 | $3.4M | $1.1M | +45.27% |
| Q1 2025 | 2025-03-31 | $2.7M | $376,089 | +15.97% |
| Q4 2024 | 2024-12-31 | $3.1M | $525,003 | +20.44% |
| Q3 2024 | 2024-09-30 | $2.9M | $875,895 | +44.01% |
| Q2 2024 | 2024-06-30 | $2.4M | $403,510 | +20.66% |
| Q1 2024 | 2024-03-31 | $2.4M | $526,215 | +28.78% |
| Q4 2023 | 2023-12-31 | $2.6M | $1.1M | +72.22% |
| Q3 2023 | 2023-09-30 | $2.0M | $1.9M | +2869.42% |
| Q2 2023 | 2023-06-30 | $2.0M | $1.9M | +2482.18% |
| Q1 2023 | 2023-03-31 | $1.8M | $1.8M | +2811.02% |
| Q4 2022 | 2022-12-31 | $1.5M | $1.5M | +6157.61% |
| Q3 2022 | 2022-09-30 | $67,025 | $36,155 | +117.12% |
| Q2 2022 | 2022-06-30 | $75,624 | $41,265 | +120.10% |
| Q1 2022 | 2022-03-31 | $62,800 | $41,262 | +191.58% |
| Q4 2021 | 2021-12-31 | $23,829 | $6,279 | +35.78% |
| Q3 2021 | 2021-09-30 | $30,870 | $20,060 | +185.57% |
| Q2 2021 | 2021-06-30 | $34,359 | $24,375 | +244.14% |
| Q1 2021 | 2021-03-31 | $21,538 | $14,319 | +198.35% |
| Q4 2020 | 2020-12-31 | $17,550 | $45,947 | — |
| Q3 2020 | 2020-09-30 | $10,810 | $8,777 | +431.73% |
| Q2 2020 | 2020-06-30 | $9,984 | $8,411 | +534.71% |
| Q1 2020 | 2020-03-31 | $7,219 | −$27,643 | −79.29% |
| Q4 2019 | 2019-12-31 | −$28,397 | −$38,048 | — |
| Q3 2019 | 2019-09-30 | $2,033 | $2,033 | — |
| Q2 2019 | 2019-06-30 | $1,573 | $1,573 | — |
| Q1 2019 | 2019-03-31 | $34,862 | $44,513 | — |
| Q4 2018 | 2018-12-31 | $9,651 | — | — |
| Q3 2018 | 2018-09-30 | $0 | $0 | — |
| Q2 2018 | 2018-06-30 | $0 | $0 | — |
| Q1 2018 | 2018-03-31 | −$9,651 | — | — |
| Q3 2017 | 2017-09-30 | $0 | — | — |
| Q2 2017 | 2017-06-30 | $0 | — | — |
Sunshine Biopharma gross profit trends
Over the last five fiscal years, Sunshine Biopharma's gross profit increased from $45,563 to $12.3M, a change of $12.2M. The latest reported quarter, Q2 2026, shows $2.4M.
What gross profit means
Gross profit is the amount of revenue remaining after the direct costs of producing and delivering a company’s goods or services. It helps show the dollars available to cover operating expenses before operating income, interest, and taxes.
SEC-reported and calculated gross profit
TickerStat uses gross profit reported in company SEC filings when available. Otherwise, it calculates gross profit as SEC-reported revenue minus aligned cost of revenue for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Sunshine Biopharma source filings ↗